论文部分内容阅读
目的检测miRNA200a在子宫肌瘤中的表达特点以及临床意义。方法选取我院收治的60例子宫肌瘤患者作为研究对象,同期健康体检女性60例作为对照组。分别采集子宫肌瘤组织和肌瘤旁正常组织、患者血清和健康人群血清存档研究,采用原位杂交法、荧光定量PCR法检测miRNA200a表达。结果 miRNA200a在子宫肌瘤组织中阳性表达率为75.0%,正常组织中为8.3%;在子宫肌瘤患者血清中的相对表达量为(4.28±0.75),健康人群中为(1.04±0.26)。P<0.05,差异有统计学意义。结论 miRNA200a在子宫肌瘤的发生发展中起到重要作用,提示医师在临床诊疗中关注miRNA200a,可能成为治疗子宫肌瘤的新靶向。
Objective To detect the expression of miRNA200a in uterine fibroids and its clinical significance. Methods Sixty patients with uterine fibroids admitted to our hospital were selected as the study subjects, and 60 healthy women during the same period were taken as the control group. The umbilical myoma tissue and normal tissue next to fibroids were collected, and the serum of healthy people and the serum of healthy people were archived. The expression of miRNA200a was detected by fluorescence quantitative PCR and in situ hybridization. Results The positive rate of miRNA200a was 75.0% in uterine fibroids and 8.3% in normal tissues. The relative expression of miRNA200a in uterine leiomyoma was (4.28 ± 0.75) in serum and (1.04 ± 0.26) in healthy people. P <0.05, the difference was statistically significant. Conclusion miRNA200a plays an important role in the development of uterine fibroids, suggesting that clinicians pay attention to miRNA200a in clinical diagnosis and treatment, which may be a new target for treating uterine fibroids.